SIEBERT JOHN M
Insider CIK 1190558 · ARDM Interim Principal Exec Ofcr, Director · SUPN Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2024-02-23 | 2024-02-27 | 3,886 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2024-02-23 | 2024-02-27 | 3,886 | — | $0 | 87,943 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2024-02-22 | 2024-02-26 | 8,252 | — | $0 | 8,252 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2024-02-22 | 2024-02-26 | 5,369 | — | $0 | 5,369 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-02-23 | 2023-02-27 | 3,886 | — | $0 | 3,886 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-02-23 | 2023-02-27 | 6,293 | — | $0 | 6,293 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2023-02-22 | 2023-02-24 | 3,882 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2023-02-22 | 2023-02-24 | 3,882 | — | $0 | 84,057 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-24 | 3,882 | — | $0 | 3,882 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-24 | 6,847 | — | $0 | 6,847 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2022-02-19 | 2022-02-23 | 4,222 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2022-02-19 | 2022-02-23 | 4,222 | — | $0 | 80,175 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2021-08-11 | 2021-08-12 | 15,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2021-08-11 | 2021-08-12 | 15,000 | $12.98 | $194.7K | 75,953 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2021-02-19 | 2021-02-23 | 4,222 | — | $0 | 4,222 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2021-02-19 | 2021-02-23 | 7,365 | — | $0 | 7,365 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2020-02-21 | 2020-02-25 | 9,305 | — | $0 | 9,305 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2020-02-21 | 2020-02-25 | 5,211 | $23.99 | $125.0K | 60,953 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2019-06-20 | 2019-06-24 | 10,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2019-06-20 | 2019-06-24 | 10,000 | $9.13 | $91.3K | 55,742 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2019-04-25 | 2019-04-29 | 10,000 | — | $0 | 10,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2019-04-25 | 2019-04-29 | 10,000 | $9.13 | $91.3K | 45,742 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2019-02-22 | 2019-02-26 | 12,427 | — | $0 | 12,427 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2019-02-22 | 2019-03-04 | 12,427 | — | $0 | 12,427 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2018-08-20 | 2019-03-04 | 7,457 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2018-08-20 | 2019-03-04 | 8,722 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2018-08-20 | 2019-03-04 | 8,722 | $7.90 | $68.9K | 28,285 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2018-08-20 | 2019-03-04 | 7,457 | $9.24 | $68.9K | 35,742 | SEC↗ |
| ARDM ARADIGM CORP | A Award deriv | 2018-03-22 | 2018-03-26 | 276,000 | — | $0 | 276,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2018-02-23 | 2018-02-27 | 8,613 | — | $0 | 8,613 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2017-06-13 | 2017-06-15 | 6,036 | — | $0 | 6,036 | SEC↗ |
| ARDM ARADIGM CORP | A Award deriv | 2017-06-01 | 2017-06-05 | 110,485 | — | $0 | 110,485 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2017-02-24 | 2017-02-27 | 7,905 | — | $0 | 7,905 | SEC↗ |
| ARDM ARADIGM CORP | A Award deriv | 2016-06-09 | 2016-06-13 | 35,941 | — | $0 | 35,941 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2016-03-01 | 2016-03-03 | 15,000 | — | $0 | 15,000 | SEC↗ |
| ARDM ARADIGM CORP | A Award deriv | 2015-11-12 | 2015-11-16 | 19,940 | — | $0 | 19,940 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2015-03-03 | 2015-03-05 | 20,000 | — | $0 | 20,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2014-12-16 | 2015-01-13 | 2,188 | — | $0 | 2,187 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2014-12-16 | 2015-01-13 | 2,188 | $4.24 | $9.3K | 19,563 | SEC↗ |
| ARDM ARADIGM CORP | A Award deriv | 2014-04-18 | 2014-04-22 | 225,000 | — | $0 | 225,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2014-01-21 | 2014-01-23 | 7,457 | — | $0 | 7,457 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2013-12-12 | 2014-01-23 | 2,187 | — | $0 | 4,375 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2013-12-12 | 2014-01-23 | 2,187 | $4.24 | $9.3K | 17,375 | SEC↗ |
| ARDM ARADIGM CORP | A Award deriv | 2013-05-22 | 2013-06-24 | 140,000 | — | $0 | 140,000 | SEC↗ |
| ARDM ARADIGM CORP | A Award | 2013-05-22 | 2013-06-24 | 100,000 | $0.15 | $15.0K | 501,697 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | P Buy | 2013-03-21 | 2013-03-25 | 3,000 | $5.50 | $16.5K | 15,188 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | A Award deriv | 2013-02-05 | 2013-02-07 | 8,722 | — | $0 | 8,722 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise deriv | 2012-12-14 | 2012-12-17 | 2,188 | — | $0 | 6,562 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | M Exercise | 2012-12-14 | 2012-12-17 | 2,188 | $4.24 | $9.3K | 12,188 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | P Buy | 2012-12-04 | 2012-12-05 | 7,000 | $8.14 | $57.0K | 10,000 | SEC↗ |
| ARDM ARADIGM CORP | A Award deriv | 2012-05-25 | 2012-06-01 | 140,000 | — | $0 | 140,000 | SEC↗ |
| ARDM ARADIGM CORP | A Award | 2012-05-25 | 2012-06-01 | 100,000 | — | $0 | 401,697 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS I | P Buy | 2012-05-04 | 2012-05-07 | 3,000 | $5.00 | $15.0K | 3,000 | SEC↗ |